CellWell record HH-376528
FDA approval of copper histidinate (Zycubo) for Menkes disease: a therapeutic breakthrough in a rare pediatric neurodegenerative disorder
M. H. Ghani; Muhammad Ahsan; Ahmad Asad Raza; Abedin Samadi
Annals of Medicine and Surgery ยท 2026
In plain language
FDA-approved copper histidinate therapy initiated within the first month of life improved survival and neurodevelopmental outcomes in selected Menkes disease patients.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-376528
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.